Treatment of Mediterranean visceral leishmaniasis.

Authors:
  • ABA Bryceson
    A Bryceson
  • PDP Desjeux
    P Desjeux

  • 1 January 1995
    • journal article
    • clinical trial
Abstract
Up-to-date information is given on the epidemiological situation of zoonotic visceral leishmaniasis (ZVL) in nine Mediterranean countries, and on drug regimens adopted in the management of ZVL patients in each country. Results of experimental and clinical trials on the efficacy and tolerability of liposomal amphotericin B in laboratory animals and in patients with ZVL are presented, as well as conclusions and recommendations on drug regimens to be used in the treatment of ZVL.